How Is Incyte's Stock Performance Compared to Other Biotech Stocks?

Yahoo

4 hours ago

With a market cap of $13.3 billion, Incyte Corporation (INCY) is a global biopharmaceutical company focused on discovering, developing, and commercializing therapies in oncology, inflammation, and autoimmunity. The Wilmington, Delaware-based company has over 2,600 employees and a manufacturing and R&D footprint across North America, Europe, and Asia.
Companies valued at $10 billion or more are generally labelled as 'large-cap' stocks, and Incyte fits this criterion perfectly. Its leadership stems from its strong portfolio of high-demand specialty drugs, notably Jakafi and Opzelura, which serve as key revenue drivers in the oncology and dermatology markets. Its robust research and development capabilities, with a diverse and advancing pipeline targeting cancer, inflammation, and autoimmune diseases, position it for long-term innovation.
The Next Trillion-Dollar Boom? 3 Stocks to Buy with 300 Million Humanoid Robots on the Horizon.
Warren Buffett's Berkshire Hathaway Now Pays 5% of All Corporate Income Taxes in America
Meta's Mark Zuckerberg Says the Technology They're Developing Will 'See What You See and Hear What You Hear'
Get exclusive insights with the FREE Barchart Brief newsletter. Subscribe now for quick, incisive midday market analysis you won't find anywhere else.
Despite that, INCY has fallen 19.9% from its 52-week high of $83.95, achieved on Nov. 8. Yet, shares of INCY have risen 8.6% over the past three months, compared to the SPDR S&P Biotech ETF's (XBI) 5.6% fall during the same time frame.
INCY is down 2.6% on a YTD basis, lagging behind XBI's 8.7% gains. However, shares of Incyte have climbed 6.4% over the past 52 weeks, compared to XBI's 10.9% fall over the same time frame.
INCY has been trading above its 200-day moving average since early June and has mostly stayed above its 50-day moving average since mid-May.
On June 16, shares of Incyte rose more than 4% following the announcement of encouraging clinical trial results for its investigational therapy targeting a blood disorder. The company reported positive data from two separate studies, which demonstrated the treatment's potential effectiveness and safety in managing the condition, likely a form of myeloproliferative neoplasm or a related hematologic disease. The strong outcomes from these trials bolstered investor confidence in the strength of Incyte's R&D pipeline and its ability to diversify beyond its flagship drug, Jakafi.
In comparison, rival Exelixis, Inc. (EXEL) outperformed INCY. Shares of Exelixis have gained 95.4% over the past 52 weeks and 30.2% on a YTD basis.
Among the 25 analysts covering the stock, there is a consensus rating of 'Moderate Buy,' and its mean price target of $75.81 indicates an upswing potential of 12.7% from the prevailing price levels.
On the date of publication, Kritika Sarmah did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on Barchart.com